Cited by 65Photodynamic Therapy Research StudiesNonmelanoma Skin Cancer StudiesPorphyrin Metabolism and Disorders

The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy

Choudry, K., Brooke, R.C.C., Farrar, W., Rhodes, L.E.·2003·British Journal of Dermatology

Abstract

BACKGROUND: In 5-aminolaevulinic acid (ALA)-photodynamic therapy (PDT), the prodrug ALA is endogenously converted to the active sensitizer protoporphyrin IX (PpIX), while further conversion of PpIX to haem requires iron. OBJECTIVES: To explore the potential of the iron chelator desferrioxamine (DFO) to enhance PpIX levels and phototoxicity in ALA-PDT. METHODS: A series of six doses of 2% ALA solution was iontophoresed into the healthy skin of each ventral forearm of 10 volunteers. One arm was pretreated with 20% DFO in aqueous cream, while the control arm received aqueous cream alone, for 16 h. At 5 h following iontophoresis, skin-surface PpIX fluorescence was measured, following which the forearms were simultaneously irradiated with 100 J cm-2 broadband red light. The phototoxic reaction was assessed at 24 h postirradiation as the minimal phototoxic dose (MPD) and with quantification of erythema. Next, eight patients with two superficial basal cell carcinomas or two plaques of Bowen's disease of similar appearance received 20% ALA topically to one lesion and 20% ALA with 20% DFO to the other, for 3 h. Skin-surface PpIX fluorescence was measured at 5 h, following which lesions were irradiated with 100 J cm-2 broadband red light. RESULTS: In healthy skin, PpIX fluorescence increased with increasing ALA dose at DFO-treated and untreated sites (P < 0.0005); PpIX fluorescence peak values were consistently higher in DFO-treated compared with control sites (P < 0.02). Erythema also correlated with ALA dose (P < 0.0005), but a significant difference between active and control sites occurred only at low ALA dose (P < 0.05). The median MPD appeared lower at the DFO-treated sites, at 6 mC vs. 12 mC (P = 0.06). In contrast, in lesional skin there was no consistent difference in PpIX fluorescence levels between those treated with and without DFO. CONCLUSIONS: While iron chelation augmented ALA-PDT phototoxicity in normal skin, this occurred only at low ALA dose. Addition of DFO does not appear to confer additional benefit in ALA-PDT of nonmelanoma skin cancers.

Integrity signals

Registry

Crossref · 10.1046/j.1365-2133.2003.05351.x

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • EDTA does not increase PpIX production in a mouse tumor model and BCC patients after ALA administration, and DFO does not enhance PpIX fluorescence in skin cancer patients.

    “Despite these promising results from many in vitro studies, EDTA does not increase PpIX production in a mouse tumor model [102] and BCC patients [103] after ALA administration, and DFO does not enhance PpIX fluorescence in skin cancer patients either [104].”

Cites

Flagged first, then by citations

1 of the 23 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Choudry, K., Brooke, R. C. C., Farrar, W., & Rhodes, L. E.
Affiliations
  • Salford Royal Hospital (GB)
  • Royal Liverpool University Hospital (GB)
Corresponding author
Rhodes, L.E.
Venue
British Journal of Dermatology
Published
2003-07
Volume
149
Issue
1
Pages
124-130
ISSN
  • 0007-0963 (ISSN-L)
  • 1365-2133
OpenAlex
W2018664136
Cited by
65
References
23
Citations by year
2026: 2 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 4 · 2015: 3 · 2014: 2 · 2013: 3 · 2012: 1
FWCI
2.44
Type
journal article
Language
en
Open access
closed
Locations
  • British Journal of Dermatology (publishedVersion)
  • PubMed (publishedVersion)
Funders
British Skin Foundation
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Porphyrin Metabolism and Disorders
Keywords
5-aminolevulinic acid, photodynamic therapy, protoporphyrin IX, deferoxamine, iron chelation, phototoxicity, iontophoresis, basal cell carcinoma, Bowen's disease, erythema, topical photosensitizer, skin cancer treatment, minimal phototoxic dose, red light
MeSH terms
Administration, Cutaneous, Adult, Aged, Aged, 80 and over, Aminolevulinic Acid, Bowen's Disease, Carcinoma, Basal Cell, Basal Cell Carcinoma, Deferoxamine, Dose-Response Relationship, Drug, Drug Therapy, Combination, Erythema, Female, Fluorescence, Humans, Iontophoresis, Iron Chelating Agents, Male, Middle Aged, Photochemotherapy, Protoporphyrins, Skin Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review